Advertisement

 

 

Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.

Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.
Author Information (click to view)

Huang WN, Tso TK,


Huang WN, Tso TK, (click to view)

Huang WN, Tso TK,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Bosnian journal of basic medical sciences 2017 09 27() doi 10.17305/bjbms.2017.2214
Abstract

Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, with a lower risk of gastrointestinal toxicity compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). We evaluated the effectiveness and tolerability of etoricoxib in extreme elderly patients with chronic pain due to osteoarthritis (OA). A prospective, single-center, single-arm study was conducted, enrolling 19 extreme elderly men with OA (mean age 85.9, range 79-96 years), who responded inadequately to NSAIDs or other analgesics. Patients were switched to etoricoxib, 60 mg once daily for 4 weeks, without prior medication washout. Data were recorded before and after etoricoxib treatment. The primary endpoint was the pain improvement, assessed using the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) after the 4-week treatment. Other endpoints included the Brief Pain Inventory Short Form (BPI-SF), Treatment Satisfaction Questionnaire for Medication (TSQM), Short Form 36 (SF36), and European Quality of Life-5 Dimensions (EQ-5D). Safety and tolerability were assessed by collecting adverse events data. After switching to etoricoxib, pain and disability measured by WOMAC index both decreased (pain, p = < 0.001; disability, p = 0.020). BPI-SF showed a significant improvement in joint function when walking and performing normal work (walking, p = 0.021; normal work, p = 0.030). SF36 scores improved for 7 out of 11 items after etoricoxib treatment (#1, p = 0.032; #4, p = 0.026; #5, p = 0.017; #6, p = 0.008; #7, p = 0.009; #8, p = 0.013; and #10, p = 0.038). EQ-5D showed a significant improvement in visual analogue scale (VAS) scores (p = 0.036). TSQM results demonstrated increased patient perceptions of overall satisfaction. No adverse events were reported. Pain relief, joint function, quality of life, and treatment satisfaction improved significantly in elderly patients with OA after etoricoxib administration.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × 4 =

[ HIDE/SHOW ]